Loading…
Pathophysiology, management, and outcome of persistent pulmonary hypertension of the newborn: a clinical review
Persistent Pulmonary Hypertension of the Newborn (PPHN) results from the failure of relaxation of the pulmonary vasculature at birth, leading to shunting of non-oxygenated blood from the pulmonary to the systemic circulation. More often, full term and near-term infants are affected, however it is no...
Saved in:
Published in: | Frontiers in pediatrics 2013-09, Vol.1, p.23-23 |
---|---|
Main Authors: | , |
Format: | Article |
Language: | English |
Subjects: | |
Citations: | Items that cite this one |
Online Access: | Get full text |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
cited_by | cdi_FETCH-LOGICAL-c459t-8ee77999ac2a6f129e9f50f454881225d1a65f74a4da33d26fd023e2f940a36e3 |
---|---|
cites | |
container_end_page | 23 |
container_issue | |
container_start_page | 23 |
container_title | Frontiers in pediatrics |
container_volume | 1 |
creator | Puthiyachirakkal, Mohammed Mhanna, Maroun J |
description | Persistent Pulmonary Hypertension of the Newborn (PPHN) results from the failure of relaxation of the pulmonary vasculature at birth, leading to shunting of non-oxygenated blood from the pulmonary to the systemic circulation. More often, full term and near-term infants are affected, however it is not uncommon to see PPHN in preterm infants who have respiratory distress syndrome. In some infants pulmonary vascular remodeling is present at birth, pointing toward the prenatal onset of the disease process. Regardless of the etiology, PPHN should be diagnosed and treated as soon as possible to avoid hypoxia related short term and long-term morbidities. The mainstay therapy is the treatment of the underlying condition along with several promising therapeutic modalities such as oxygen supplementation, mechanical ventilation, nitric oxide, phosphodiesterase inhibitors, prostaglandins analogs, endothelin receptor antagonists, and extracorporeal membrane oxygenation. The optimal approach to the management of PPHN remains controversial. After discharge from the NICU, infants with PPHN warrant long-term follow up since they are at risk for neurodevelopmental disabilities and chronic health conditions. |
doi_str_mv | 10.3389/fped.2013.00023 |
format | article |
fullrecord | <record><control><sourceid>proquest_doaj_</sourceid><recordid>TN_cdi_doaj_primary_oai_doaj_org_article_aa58ceab791c4040b99ca173afd90b9a</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><doaj_id>oai_doaj_org_article_aa58ceab791c4040b99ca173afd90b9a</doaj_id><sourcerecordid>1540109310</sourcerecordid><originalsourceid>FETCH-LOGICAL-c459t-8ee77999ac2a6f129e9f50f454881225d1a65f74a4da33d26fd023e2f940a36e3</originalsourceid><addsrcrecordid>eNpVkUlPHDEQhVsoUUCEc27IxxyYwVsvziFShLIgISUHOFs17vK0kdvu2N2g-ffxMATByfarV5_LflX1idG1EJ26tBP2a06ZWFNKuTiqTjhXzYqLhr57tT-uznK-LxaqWlqz-kN1zKUsHY06qeIfmIc4Dbvsoo_b3QUZIcAWRwzzBYHQk7jMJo5IoiUTpuzyXEpkWvwYA6QdGXZFLloBhL1pHpAEfNzEFL4QIMa74Ax4kvDB4ePH6r0Fn_HseT2t7n58v736tbr5_fP66tvNyshazasOsW2VUmA4NJZxhcrW1Mpadh3jvO4ZNLVtJcgehOh5Y_vyA8itkhREg-K0uj5w-wj3ekpuLLPqCE4_CTFtNaTZGY8aoO4MwqZVzEgq6UYpA6wVYHtVDlBYXw-sadmM2Jvy_gT-DfRtJbhBb-ODFl0jmeoK4PMzIMW_C-ZZjy4b9B4CxiVrVkvKqBKMFuvlwWpSzDmhfbmGUb1PXe9T1_vU9VPqpeP89XQv_v8Zi3-ToquT</addsrcrecordid><sourcetype>Open Website</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1540109310</pqid></control><display><type>article</type><title>Pathophysiology, management, and outcome of persistent pulmonary hypertension of the newborn: a clinical review</title><source>Open Access: PubMed Central</source><creator>Puthiyachirakkal, Mohammed ; Mhanna, Maroun J</creator><creatorcontrib>Puthiyachirakkal, Mohammed ; Mhanna, Maroun J</creatorcontrib><description>Persistent Pulmonary Hypertension of the Newborn (PPHN) results from the failure of relaxation of the pulmonary vasculature at birth, leading to shunting of non-oxygenated blood from the pulmonary to the systemic circulation. More often, full term and near-term infants are affected, however it is not uncommon to see PPHN in preterm infants who have respiratory distress syndrome. In some infants pulmonary vascular remodeling is present at birth, pointing toward the prenatal onset of the disease process. Regardless of the etiology, PPHN should be diagnosed and treated as soon as possible to avoid hypoxia related short term and long-term morbidities. The mainstay therapy is the treatment of the underlying condition along with several promising therapeutic modalities such as oxygen supplementation, mechanical ventilation, nitric oxide, phosphodiesterase inhibitors, prostaglandins analogs, endothelin receptor antagonists, and extracorporeal membrane oxygenation. The optimal approach to the management of PPHN remains controversial. After discharge from the NICU, infants with PPHN warrant long-term follow up since they are at risk for neurodevelopmental disabilities and chronic health conditions.</description><identifier>ISSN: 2296-2360</identifier><identifier>EISSN: 2296-2360</identifier><identifier>DOI: 10.3389/fped.2013.00023</identifier><identifier>PMID: 24400269</identifier><language>eng</language><publisher>Switzerland: Frontiers Media S.A</publisher><subject>Newborn ; Outcome ; pathophysiology ; Pediatrics ; Persistent Pulmonary Hypertension ; Treatment</subject><ispartof>Frontiers in pediatrics, 2013-09, Vol.1, p.23-23</ispartof><rights>Copyright © 2013 Puthiyachirakkal and Mhanna. 2013</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c459t-8ee77999ac2a6f129e9f50f454881225d1a65f74a4da33d26fd023e2f940a36e3</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC3864198/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC3864198/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,727,780,784,885,27924,27925,53791,53793</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/24400269$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Puthiyachirakkal, Mohammed</creatorcontrib><creatorcontrib>Mhanna, Maroun J</creatorcontrib><title>Pathophysiology, management, and outcome of persistent pulmonary hypertension of the newborn: a clinical review</title><title>Frontiers in pediatrics</title><addtitle>Front Pediatr</addtitle><description>Persistent Pulmonary Hypertension of the Newborn (PPHN) results from the failure of relaxation of the pulmonary vasculature at birth, leading to shunting of non-oxygenated blood from the pulmonary to the systemic circulation. More often, full term and near-term infants are affected, however it is not uncommon to see PPHN in preterm infants who have respiratory distress syndrome. In some infants pulmonary vascular remodeling is present at birth, pointing toward the prenatal onset of the disease process. Regardless of the etiology, PPHN should be diagnosed and treated as soon as possible to avoid hypoxia related short term and long-term morbidities. The mainstay therapy is the treatment of the underlying condition along with several promising therapeutic modalities such as oxygen supplementation, mechanical ventilation, nitric oxide, phosphodiesterase inhibitors, prostaglandins analogs, endothelin receptor antagonists, and extracorporeal membrane oxygenation. The optimal approach to the management of PPHN remains controversial. After discharge from the NICU, infants with PPHN warrant long-term follow up since they are at risk for neurodevelopmental disabilities and chronic health conditions.</description><subject>Newborn</subject><subject>Outcome</subject><subject>pathophysiology</subject><subject>Pediatrics</subject><subject>Persistent Pulmonary Hypertension</subject><subject>Treatment</subject><issn>2296-2360</issn><issn>2296-2360</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2013</creationdate><recordtype>article</recordtype><sourceid>DOA</sourceid><recordid>eNpVkUlPHDEQhVsoUUCEc27IxxyYwVsvziFShLIgISUHOFs17vK0kdvu2N2g-ffxMATByfarV5_LflX1idG1EJ26tBP2a06ZWFNKuTiqTjhXzYqLhr57tT-uznK-LxaqWlqz-kN1zKUsHY06qeIfmIc4Dbvsoo_b3QUZIcAWRwzzBYHQk7jMJo5IoiUTpuzyXEpkWvwYA6QdGXZFLloBhL1pHpAEfNzEFL4QIMa74Ax4kvDB4ePH6r0Fn_HseT2t7n58v736tbr5_fP66tvNyshazasOsW2VUmA4NJZxhcrW1Mpadh3jvO4ZNLVtJcgehOh5Y_vyA8itkhREg-K0uj5w-wj3ekpuLLPqCE4_CTFtNaTZGY8aoO4MwqZVzEgq6UYpA6wVYHtVDlBYXw-sadmM2Jvy_gT-DfRtJbhBb-ODFl0jmeoK4PMzIMW_C-ZZjy4b9B4CxiVrVkvKqBKMFuvlwWpSzDmhfbmGUb1PXe9T1_vU9VPqpeP89XQv_v8Zi3-ToquT</recordid><startdate>20130902</startdate><enddate>20130902</enddate><creator>Puthiyachirakkal, Mohammed</creator><creator>Mhanna, Maroun J</creator><general>Frontiers Media S.A</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>5PM</scope><scope>DOA</scope></search><sort><creationdate>20130902</creationdate><title>Pathophysiology, management, and outcome of persistent pulmonary hypertension of the newborn: a clinical review</title><author>Puthiyachirakkal, Mohammed ; Mhanna, Maroun J</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c459t-8ee77999ac2a6f129e9f50f454881225d1a65f74a4da33d26fd023e2f940a36e3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2013</creationdate><topic>Newborn</topic><topic>Outcome</topic><topic>pathophysiology</topic><topic>Pediatrics</topic><topic>Persistent Pulmonary Hypertension</topic><topic>Treatment</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Puthiyachirakkal, Mohammed</creatorcontrib><creatorcontrib>Mhanna, Maroun J</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><collection>Directory of Open Access Journals</collection><jtitle>Frontiers in pediatrics</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Puthiyachirakkal, Mohammed</au><au>Mhanna, Maroun J</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Pathophysiology, management, and outcome of persistent pulmonary hypertension of the newborn: a clinical review</atitle><jtitle>Frontiers in pediatrics</jtitle><addtitle>Front Pediatr</addtitle><date>2013-09-02</date><risdate>2013</risdate><volume>1</volume><spage>23</spage><epage>23</epage><pages>23-23</pages><issn>2296-2360</issn><eissn>2296-2360</eissn><abstract>Persistent Pulmonary Hypertension of the Newborn (PPHN) results from the failure of relaxation of the pulmonary vasculature at birth, leading to shunting of non-oxygenated blood from the pulmonary to the systemic circulation. More often, full term and near-term infants are affected, however it is not uncommon to see PPHN in preterm infants who have respiratory distress syndrome. In some infants pulmonary vascular remodeling is present at birth, pointing toward the prenatal onset of the disease process. Regardless of the etiology, PPHN should be diagnosed and treated as soon as possible to avoid hypoxia related short term and long-term morbidities. The mainstay therapy is the treatment of the underlying condition along with several promising therapeutic modalities such as oxygen supplementation, mechanical ventilation, nitric oxide, phosphodiesterase inhibitors, prostaglandins analogs, endothelin receptor antagonists, and extracorporeal membrane oxygenation. The optimal approach to the management of PPHN remains controversial. After discharge from the NICU, infants with PPHN warrant long-term follow up since they are at risk for neurodevelopmental disabilities and chronic health conditions.</abstract><cop>Switzerland</cop><pub>Frontiers Media S.A</pub><pmid>24400269</pmid><doi>10.3389/fped.2013.00023</doi><tpages>1</tpages><oa>free_for_read</oa></addata></record> |
fulltext | fulltext |
identifier | ISSN: 2296-2360 |
ispartof | Frontiers in pediatrics, 2013-09, Vol.1, p.23-23 |
issn | 2296-2360 2296-2360 |
language | eng |
recordid | cdi_doaj_primary_oai_doaj_org_article_aa58ceab791c4040b99ca173afd90b9a |
source | Open Access: PubMed Central |
subjects | Newborn Outcome pathophysiology Pediatrics Persistent Pulmonary Hypertension Treatment |
title | Pathophysiology, management, and outcome of persistent pulmonary hypertension of the newborn: a clinical review |
url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-25T20%3A38%3A27IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_doaj_&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Pathophysiology,%20management,%20and%20outcome%20of%20persistent%20pulmonary%20hypertension%20of%20the%20newborn:%20a%20clinical%20review&rft.jtitle=Frontiers%20in%20pediatrics&rft.au=Puthiyachirakkal,%20Mohammed&rft.date=2013-09-02&rft.volume=1&rft.spage=23&rft.epage=23&rft.pages=23-23&rft.issn=2296-2360&rft.eissn=2296-2360&rft_id=info:doi/10.3389/fped.2013.00023&rft_dat=%3Cproquest_doaj_%3E1540109310%3C/proquest_doaj_%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c459t-8ee77999ac2a6f129e9f50f454881225d1a65f74a4da33d26fd023e2f940a36e3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=1540109310&rft_id=info:pmid/24400269&rfr_iscdi=true |